|Study Name||Who's Treated?||Age||Treatment components||Duration||Study Status|
|Gabapentin for Benzodiazepine Dependence||Benzodiazepine users||18-65||Gabapentin or placebo (double-blind)
Individual sessions of medical management therapy weekly
|12-week outpatient medication trial requiring multiple clinic visits per week||Active and recruiting participants|
This research study will help us determine if gabapentin (Neurontin®) is helpful in treating Benzodiazepine dependence. Gabapentin is not currently approved by the FDA for treating Benzodiazepine dependence. It is currently FDA-approved for epilepsy and postherpetic neuralgia. Therefore, we do not know if it will help you reduce or stop your Benzodiazepine use. If you participate, you will be treated with either gabapentin or placebo (i.e., a pill that looks the same as gabapentin but does not contain any active medication) for the duration of the study, which is twelve weeks.
Type of Treatment:
This study involves twelve weeks of outpatient medication treatment. Patients need to make clinic visits five times the first week, three times the second week, and then twice a week for the remainder of the eight-week study. The twice-weekly visits to STARS should take between thirty and sixty minutes. Study visits will include monitoring of vital signs and urine for drugs of abuse, completion of questionnaires and brief interviews about drug use and medication, and one visit each week will include a meeting with the psychiatrist for psychotherapy and medical assessment. Medication will be dispensed once per week during a study visit to be taken at home daily. After the study is finished, patients are able to continue meeting with staff for four weeks. This is to go over progress made during the trial and to find referrals for continued treatment if requested.
Cutting edge approaches to treating addiction to marijuana, benzodiazepines, cocaine, heroin or narcotic painkillers are available in a supportive and professional environment.